PI3-Kinase alpha is a complex of N-terminal 6X His-tagged recombinant full-length human p110alpha and untagged, recombinant, full-length, human p85alpha
Storage: Store product > -70 oC. Enzyme is stable for at least 6 months at -70 oC as undiluted stockSpecificity: PI3-K selectively adds phosphate to the 3’ position of the inositol ring of PtdIns(4,5)P2GenBank Accession number: p110alpha – NM_006218; p85alpha – NM_181523.1Specific Activity: request Certificate of Analysis (COA)
The recombinant p110alpha and p85alpha proteins for PI3-Kinase alpha were co-expressed in sf9 cells using baculovirus expression vector system and purified by affinity chromatography. This enzyme complex is tested for activity against PI(4,5)P2 in the PI3-Kinase activity assay.
Phosphoinositide-3-kinases (PI3-k) are a family of lipid kinases classified into three classes (I, II, III) based on their catalytic domain. The Class 1 PI3-k, which produce PI(3,4,5)P3 in vivo, is comprised of a 110 kDa catalytic subunit and a regulatory subunit. There are four isoforms in Class I. Three isoforms termed alpha, beta and delta (gene names PIK3CA, PIK3CB, and PI3KCD) in Class IAand one isoform in Class IB called gamma (PI3KCG). Class IA enzymes are preferentially activated by tyrosine-kinase-mediated signals, while Class IB enzyme is linked to G-protein-coupled receptors (GPCR).
Mounting evidence implicates a role for PI3-k in numerous human diseases including: allergy, inflammation, heart disease, diabetes, hypertension and cancer. Therefore, the inhibitors of PI3-k are considered potential important therapeutic agents.